Research & Development
Scientists at Herbology International use an inquisitive drug hunting approach to discover and develop homeopathic medicines to improve patients' lives.
From the outset, Herbology’s founder wanted to create a company with a bold, pioneering spirit, one that understands the true nature of innovation. The founders understood that innovation could not be taught, but the right environment to allow innovation can be fostered. Herbology’s productivity is evidence that from creative freedom, innovative ideas flourish.
By removing the barriers to innovation, such as bureaucracy and hierarchy, the founders set out to empower “their” people. In turn, Herbology’s people take ownership of their projects and grasp opportunities.
There are many barriers to overcome when guiding a compound that addresses an unmet medical need from the bench to the market. To maximize success, the Research and Development teams must know which projects are most promising, which compounds should be promoted, and where to focus their efforts.
The only way to make the correct choices is to base these decisions on all facts available. This means open, effective communication within teams and across functions in an integrated approach.
This sharing of knowledge stimulates and builds scientific intuition. By using this approach, innovation can be translated into evidence-based medicine.
We currently are developing a portfolio of our five most advanced product candidates, including three product candidates in clinical development and two product candidates in IND-track development. Our pipeline addresses diseases that are not well served by currently available therapies and represent large potential commercial opportunities. We believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies.
Our most advanced product candidates include HBINTL-24 in Phase III development for fibromyalgia, HBINTL-25 in Phase II for common cold and HBINTL-26 in Phase I for chronic pain and two product candidates in IND-track development.
 |
Premier Drug Fluendz |
FREQUENTLY ASKED QUESTIONS
